Literature DB >> 17620433

TNF-alpha-based accentuation in cryoinjury--dose, delivery, and response.

Raghav Goel1, David Swanlund, James Coad, Guilio F Paciotti, John C Bischof.   

Abstract

Cryosurgery is a minimally invasive cancer treatment using cryogenic temperatures. Intraoperative monitoring of iceball growth is an advantage of the treatment. However, whereas the iceball can be easily visualized, destruction within the iceball is incomplete and the means to monitor the "kill zone" are urgently needed. Recently, we have shown the ability of tumor necrosis factor-alpha (TNF-alpha) to enhance destruction within an iceball. To avoid systemic toxicity, we delivered TNF-alpha selectively to the tumor by a gold nanoparticle of 30-nm diameter (CYT-6091) tagged with TNF-alpha and thiol-derivatized polyethylene glycol. Using a dorsal skin fold chamber (DSFC) in a nude mouse, both normal skin and human prostate carcinoma (LNCaP Pro 5) were pretreated with soluble TNF-alpha (topically or i.v.) or CYT-6091 (i.v.) and frozen after 4 h. The cryolesion was assessed after 3 days by comparing histologic necrosis with perfusion defects. Hind limb tumors were also treated by visibly encompassing the tumor with an iceball and assessing gross changes over time. A 5-mug dose of soluble TNF-alpha or CYT-6091 increased the temperature threshold of necrosis in the tumor in the DSFC from -14.0 +/- 1.6 degrees C (n = 6) to 0.9 +/- 1.5 degrees C (n = 6) and -1.5 +/- 3.7 degrees C (n = 6), respectively. In hind limb tumors, the same dose resulted in significant tumor shrinkage and remission in 2 of 8 (for soluble TNF-alpha) and in 3 of 8 (for CYT-6091). The nanoparticle alone group without TNF-alpha increased the temperature threshold of necrosis to -7.0 +/- 2.3 degrees C in the tumor in the DSFC and more shrinkage of the tumor in the hind limb when compared with cryo alone treatment. Systemic toxicity was noted in all soluble TNF-alpha groups but none with CYT-6091. These results suggest that it is possible to destroy all of a tumor within an iceball by preincubation with TNF-alpha and systemic toxicity can be avoided by CYT-6091.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620433     DOI: 10.1158/1535-7163.MCT-06-0676

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  23 in total

1.  Blood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties.

Authors:  Neha B Shah; Gregory M Vercellotti; James G White; Adrian Fegan; Carston R Wagner; John C Bischof
Journal:  Mol Pharm       Date:  2012-07-23       Impact factor: 4.939

2.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 3.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

4.  In vivo detection of the effects of preconditioning on LNCaP tumors by a TNF-α nanoparticle construct using MRI.

Authors:  Isabelle Iltis; Jeunghwan Choi; Manda Vollmers; Mithun Shenoi; John Bischof; Gregory J Metzger
Journal:  NMR Biomed       Date:  2014-07-01       Impact factor: 4.044

5.  Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

Authors:  Mithun M Shenoi; Isabelle Iltis; Jeunghwan Choi; Nathan A Koonce; Gregory J Metzger; Robert J Griffin; John C Bischof
Journal:  Mol Pharm       Date:  2013-04-17       Impact factor: 4.939

Review 6.  Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue.

Authors:  J G Baust; J C Bischof; S Jiang-Hughes; T J Polascik; D B Rukstalis; A A Gage; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-01-27       Impact factor: 5.554

7.  Enhanced cancer therapy with cold-controlled drug release and photothermal warming enabled by one nanoplatform.

Authors:  Hai Wang; Pranay Agarwal; Yutong Liang; Jiangsheng Xu; Gang Zhao; Katherine H R Tkaczuk; Xiongbin Lu; Xiaoming He
Journal:  Biomaterials       Date:  2018-07-17       Impact factor: 12.479

Review 8.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

Review 9.  Experimental cryosurgery investigations in vivo.

Authors:  A A Gage; J M Baust; J G Baust
Journal:  Cryobiology       Date:  2009-10-13       Impact factor: 2.487

Review 10.  Applications of gold nanoparticles in cancer nanotechnology.

Authors:  Weibo Cai; Ting Gao; Hao Hong; Jiangtao Sun
Journal:  Nanotechnol Sci Appl       Date:  2008-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.